First Citizens Bank & Trust Co. raised its stake in shares of Danaher Co. (NYSE:DHR – Free Report) by 0.5% during the 3rd quarter, Holdings Channel.com reports. The fund owned 39,861 shares of the conglomerate’s stock after acquiring an additional 207 shares during the period. First Citizens Bank & Trust Co.’s holdings in Danaher were worth $11,082,000 as of its most recent SEC filing.
A number of other hedge funds have also recently bought and sold shares of DHR. Blue Trust Inc. grew its position in Danaher by 9.1% in the 3rd quarter. Blue Trust Inc. now owns 9,458 shares of the conglomerate’s stock worth $2,630,000 after purchasing an additional 786 shares in the last quarter. Dixon Mitchell Investment Counsel Inc. boosted its stake in shares of Danaher by 5.4% in the 3rd quarter. Dixon Mitchell Investment Counsel Inc. now owns 131,440 shares of the conglomerate’s stock worth $36,578,000 after buying an additional 6,688 shares during the last quarter. Meridian Financial Partners LLC grew its holdings in shares of Danaher by 4.4% in the third quarter. Meridian Financial Partners LLC now owns 957 shares of the conglomerate’s stock valued at $266,000 after acquiring an additional 40 shares in the last quarter. West Oak Capital LLC increased its position in shares of Danaher by 1.6% during the third quarter. West Oak Capital LLC now owns 10,461 shares of the conglomerate’s stock valued at $2,908,000 after acquiring an additional 165 shares during the last quarter. Finally, Moss Adams Wealth Advisors LLC lifted its holdings in Danaher by 4.7% during the third quarter. Moss Adams Wealth Advisors LLC now owns 4,049 shares of the conglomerate’s stock worth $1,127,000 after acquiring an additional 181 shares during the period. 79.05% of the stock is owned by hedge funds and other institutional investors.
Insider Buying and Selling at Danaher
In related news, CEO Rainer Blair sold 9,007 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the sale, the chief executive officer now owns 97,983 shares in the company, valued at $27,435,240. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other news, CEO Rainer Blair sold 9,007 shares of Danaher stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the transaction, the chief executive officer now owns 97,983 shares in the company, valued at approximately $27,435,240. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Brian W. Ellis sold 9,600 shares of Danaher stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the completion of the transaction, the senior vice president now directly owns 20,230 shares in the company, valued at $5,566,486.80. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 39,659 shares of company stock worth $11,042,433 over the last 90 days. Corporate insiders own 11.10% of the company’s stock.
Danaher Trading Up 0.9 %
Danaher (NYSE:DHR – Get Free Report) last posted its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.57 by $0.15. The company had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm’s quarterly revenue was down 2.9% on a year-over-year basis. During the same quarter last year, the company earned $2.05 earnings per share. On average, equities analysts expect that Danaher Co. will post 7.59 earnings per share for the current fiscal year.
Danaher Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be given a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a dividend yield of 0.39%. The ex-dividend date of this dividend is Friday, September 27th. Danaher’s dividend payout ratio (DPR) is currently 18.31%.
Wall Street Analyst Weigh In
DHR has been the subject of several research analyst reports. Barclays raised their target price on Danaher from $270.00 to $285.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 24th. Wells Fargo & Company began coverage on shares of Danaher in a report on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 price objective for the company. Stephens assumed coverage on shares of Danaher in a research note on Tuesday, October 1st. They issued an “overweight” rating and a $315.00 target price on the stock. Robert W. Baird raised their price target on shares of Danaher from $271.00 to $278.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. Finally, Evercore ISI lifted their price target on shares of Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Seven analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $282.12.
Danaher Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Further Reading
- Five stocks we like better than Danaher
- How to invest in marijuana stocks in 7 steps
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- What Is WallStreetBets and What Stocks Are They Targeting?
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
- Why Invest in 5G? How to Invest in 5G Stocks
- MarketBeat Week in Review – 10/14 – 10/18
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.